JP2017048250A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017048250A5 JP2017048250A5 JP2016238150A JP2016238150A JP2017048250A5 JP 2017048250 A5 JP2017048250 A5 JP 2017048250A5 JP 2016238150 A JP2016238150 A JP 2016238150A JP 2016238150 A JP2016238150 A JP 2016238150A JP 2017048250 A5 JP2017048250 A5 JP 2017048250A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- pharmaceutical composition
- liquid pharmaceutical
- use according
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 239000007788 liquid Substances 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 8
- -1 isomers Chemical class 0.000 claims 7
- 229940124597 therapeutic agent Drugs 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 6
- 239000007922 nasal spray Substances 0.000 claims 5
- 229940097496 nasal spray Drugs 0.000 claims 5
- 239000002202 Polyethylene glycol Substances 0.000 claims 3
- 229920001223 polyethylene glycol Polymers 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 229940122236 Histamine receptor antagonist Drugs 0.000 claims 2
- 239000004004 anti-anginal agent Substances 0.000 claims 2
- 230000001430 anti-depressive effect Effects 0.000 claims 2
- 230000000078 anti-malarial effect Effects 0.000 claims 2
- 230000002460 anti-migrenic effect Effects 0.000 claims 2
- 230000001022 anti-muscarinic effect Effects 0.000 claims 2
- 229940035678 anti-parkinson drug Drugs 0.000 claims 2
- 230000000842 anti-protozoal effect Effects 0.000 claims 2
- 230000003208 anti-thyroid effect Effects 0.000 claims 2
- 230000000259 anti-tumor effect Effects 0.000 claims 2
- 239000003416 antiarrhythmic agent Substances 0.000 claims 2
- 239000000924 antiasthmatic agent Substances 0.000 claims 2
- 239000003146 anticoagulant agent Substances 0.000 claims 2
- 239000001961 anticonvulsive agent Substances 0.000 claims 2
- 239000000935 antidepressant agent Substances 0.000 claims 2
- 229940005513 antidepressants Drugs 0.000 claims 2
- 239000003472 antidiabetic agent Substances 0.000 claims 2
- 229940121375 antifungal agent Drugs 0.000 claims 2
- 239000000739 antihistaminic agent Substances 0.000 claims 2
- 229940125715 antihistaminic agent Drugs 0.000 claims 2
- 239000003430 antimalarial agent Substances 0.000 claims 2
- 239000003904 antiprotozoal agent Substances 0.000 claims 2
- 229940043671 antithyroid preparations Drugs 0.000 claims 2
- 239000002249 anxiolytic agent Substances 0.000 claims 2
- 230000000949 anxiolytic effect Effects 0.000 claims 2
- 239000002876 beta blocker Substances 0.000 claims 2
- 229940097320 beta blocking agent Drugs 0.000 claims 2
- 230000003177 cardiotonic effect Effects 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 229960001334 corticosteroids Drugs 0.000 claims 2
- 239000002934 diuretic Substances 0.000 claims 2
- 229940030606 diuretics Drugs 0.000 claims 2
- 239000004083 gastrointestinal agent Substances 0.000 claims 2
- 229940127227 gastrointestinal drug Drugs 0.000 claims 2
- 239000003163 gonadal steroid hormone Substances 0.000 claims 2
- 230000000147 hypnotic effect Effects 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 229940035363 muscle relaxants Drugs 0.000 claims 2
- 239000003158 myorelaxant agent Substances 0.000 claims 2
- 239000003176 neuroleptic agent Substances 0.000 claims 2
- 230000000701 neuroleptic effect Effects 0.000 claims 2
- 150000002823 nitrates Chemical class 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 239000002777 nucleoside Substances 0.000 claims 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 235000015097 nutrients Nutrition 0.000 claims 2
- 239000000014 opioid analgesic Substances 0.000 claims 2
- 229940005483 opioid analgesics Drugs 0.000 claims 2
- 239000000816 peptidomimetic Substances 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 239000000932 sedative agent Substances 0.000 claims 2
- 230000001624 sedative effect Effects 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 230000003288 anthiarrhythmic effect Effects 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000001088 anti-asthma Effects 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 claims 1
- 230000003178 anti-diabetic effect Effects 0.000 claims 1
- 230000003556 anti-epileptic effect Effects 0.000 claims 1
- 230000000843 anti-fungal effect Effects 0.000 claims 1
- 230000003276 anti-hypertensive effect Effects 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 229940127090 anticoagulant agent Drugs 0.000 claims 1
- 229940127219 anticoagulant drug Drugs 0.000 claims 1
- 229940125708 antidiabetic agent Drugs 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229940030600 antihypertensive agent Drugs 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 125000003310 benzodiazepinyl group Chemical group N1N=C(C=CC2=C1C=CC=C2)* 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 150000002170 ethers Chemical class 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 229960003793 midazolam Drugs 0.000 claims 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 claims 1
- 210000002850 nasal mucosa Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IS8593 | 2007-01-19 | ||
| IS8593 | 2007-01-19 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015231350A Division JP6084277B2 (ja) | 2007-01-19 | 2015-11-27 | 治療薬を送達するための方法および組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017117506A Division JP2017155060A (ja) | 2007-01-19 | 2017-06-15 | 治療薬を送達するための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017048250A JP2017048250A (ja) | 2017-03-09 |
| JP2017048250A5 true JP2017048250A5 (https=) | 2017-07-27 |
| JP6295314B2 JP6295314B2 (ja) | 2018-03-14 |
Family
ID=39512543
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009546547A Active JP5877939B2 (ja) | 2007-01-19 | 2008-01-18 | 治療薬を送達するための方法および組成物 |
| JP2013169582A Pending JP2013231089A (ja) | 2007-01-19 | 2013-08-19 | 治療薬を送達するための方法および組成物 |
| JP2015231350A Active JP6084277B2 (ja) | 2007-01-19 | 2015-11-27 | 治療薬を送達するための方法および組成物 |
| JP2016238150A Active JP6295314B2 (ja) | 2007-01-19 | 2016-12-08 | 治療薬を送達するための方法および組成物 |
| JP2017117506A Pending JP2017155060A (ja) | 2007-01-19 | 2017-06-15 | 治療薬を送達するための方法および組成物 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009546547A Active JP5877939B2 (ja) | 2007-01-19 | 2008-01-18 | 治療薬を送達するための方法および組成物 |
| JP2013169582A Pending JP2013231089A (ja) | 2007-01-19 | 2013-08-19 | 治療薬を送達するための方法および組成物 |
| JP2015231350A Active JP6084277B2 (ja) | 2007-01-19 | 2015-11-27 | 治療薬を送達するための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017117506A Pending JP2017155060A (ja) | 2007-01-19 | 2017-06-15 | 治療薬を送達するための方法および組成物 |
Country Status (11)
| Country | Link |
|---|---|
| EP (2) | EP3150230A1 (https=) |
| JP (5) | JP5877939B2 (https=) |
| CN (3) | CN101678112B (https=) |
| AU (1) | AU2008206105B2 (https=) |
| CA (1) | CA2676010C (https=) |
| DK (1) | DK2121025T3 (https=) |
| ES (1) | ES2611995T3 (https=) |
| HU (1) | HUE031463T2 (https=) |
| IL (1) | IL199904A (https=) |
| PL (1) | PL2121025T3 (https=) |
| WO (1) | WO2008089426A2 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0720716D0 (en) * | 2007-10-23 | 2007-12-05 | York Pharma Plc | Novel formulation |
| GB2481407B (en) * | 2010-06-22 | 2012-05-23 | Special Products Ltd | A rapid onset liquid midazolam composition for buccal administration |
| MY194947A (en) * | 2011-05-13 | 2022-12-27 | Euro Celtique Sa | Intranasal pharmaceutical dosage forms comprising naloxone |
| WO2019049145A1 (en) * | 2017-09-11 | 2019-03-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | COMPOSITIONS AND METHODS FOR NASAL BRAIN MEDICATION ADMINISTRATION FOR SYSTEMIC EFFECT |
| JP2019099557A (ja) * | 2017-11-28 | 2019-06-24 | 日本化薬株式会社 | ベンダムスチンを含有する溶液製剤 |
| WO2019226753A1 (en) | 2018-05-25 | 2019-11-28 | Ucb Biopharma Sprl | Benzodiazepine formulations |
| CN111388481A (zh) * | 2020-03-20 | 2020-07-10 | 浙江美华鼎昌医药科技有限公司 | 一种咪达唑仑和丙戊酸钠的药物组合物及其制备方法 |
| CN114588116B (zh) * | 2020-12-04 | 2024-03-15 | 四川科瑞德制药股份有限公司 | 磷苯妥英钠固体组合物、冻干方法、及其用途 |
| CN113274482B (zh) * | 2021-06-07 | 2023-09-05 | 穆琳 | 缩宫素或其衍生物在制备治疗或改善贫乳的制剂中的用途以及组合物 |
| WO2024142091A1 (en) * | 2022-12-26 | 2024-07-04 | Cipla Limited | Stable aqueous injectable formulation of flucytosine |
| CN119488471A (zh) * | 2023-08-17 | 2025-02-21 | 纳索菲德(上海)制药技术有限公司 | 一种尼莫地平鼻脑递释制剂、其制备方法及其用途 |
| WO2025115019A1 (en) * | 2023-11-30 | 2025-06-05 | Padagis Israel Pharmaceuticals Ltd. | Stable nitroglycerin formulations |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4153689A (en) | 1975-06-13 | 1979-05-08 | Takeda Chemical Industries, Ltd. | Stable insulin preparation for nasal administration |
| US4863720A (en) * | 1986-03-10 | 1989-09-05 | Walter Burghart | Pharmaceutical preparation and methods for its production |
| US4782047A (en) | 1986-05-22 | 1988-11-01 | Syntex Pharmaceuticals International Ltd. | Aqueous steroid formulations for nasal administration |
| DE3734306A1 (de) | 1987-10-10 | 1989-04-27 | Pfeiffer Erich Gmbh & Co Kg | Austragvorrichtung fuer fliessfaehige medien |
| ES2117642T3 (es) | 1990-05-10 | 1998-08-16 | Bechgaard Int Res | Preparado farmaceutico que contiene n-glicofuroles y n-etilen glicoles. |
| US5338732A (en) * | 1991-06-18 | 1994-08-16 | Bristol-Myers Squibb Company | Megestrol acetate formulation |
| GB9125699D0 (en) | 1991-12-03 | 1992-01-29 | Glaxo Group Ltd | Device |
| US5897880A (en) * | 1995-09-29 | 1999-04-27 | Lam Pharmaceuticals, Llc. | Topical drug preparations |
| RU2203085C2 (ru) * | 1996-07-03 | 2003-04-27 | Элзэ Копэрейшн | Стабильный неводный препарат пептидного соединения, способ его получения и способ лечения гормон-зависимого заболевания у субъекта |
| MXPA02001612A (es) * | 1999-07-26 | 2003-10-14 | Sk Corp | Composiciones anti-convulsivas transnasales y procedimiento modular. |
| KR100360827B1 (ko) * | 1999-08-14 | 2002-11-18 | 주식회사 삼양사 | 난용성 약물을 가용화하기 위한 고분자 조성물 및 그의 제조방법 |
| KR100345214B1 (ko) * | 1999-08-17 | 2002-07-25 | 이강춘 | 생체적합성 고분자가 수식된 펩타이드의 비점막 전달 |
| DE19940236A1 (de) | 1999-08-25 | 2001-03-08 | Pfeiffer Erich Gmbh & Co Kg | Spender mit manuell betätigbarer Ausbringeinrichtung |
| US20020037319A1 (en) * | 1999-11-08 | 2002-03-28 | Alan Drizen | Drug preparations |
| US6610271B2 (en) * | 2000-05-10 | 2003-08-26 | University Of Kentucky Research Foundation | System and method for intranasal administration of lorazepam |
| EP1315533A4 (en) | 2000-08-15 | 2007-06-27 | Univ Kentucky Res Found | PROGRAMMABLE MULTI-DOSE DEVICE FOR INTRANASAL MEDICINE ADMINISTRATION |
| JP2005531570A (ja) * | 2002-05-23 | 2005-10-20 | ユーエムディー， インコーポレイテッド | 貫粘膜薬物送達及び凍結保護のための組成物及び方法 |
| JP4542743B2 (ja) * | 2002-12-26 | 2010-09-15 | Ｋｄｌ株式会社 | ピリドン誘導体の溶液状医薬組成物 |
| JP2007070225A (ja) * | 2003-07-25 | 2007-03-22 | Yukako Fujinaga | クロストリジウム属菌由来成分を含む医薬製剤 |
| WO2005027977A2 (en) * | 2003-09-22 | 2005-03-31 | Agis Industries (1983) Ltd. | Diclofenac compositions for the treatment of skin disorders |
| EP1686976A2 (en) * | 2003-11-05 | 2006-08-09 | Santarus, Inc. | Combination of proton pump inhibitor and sleep aid |
| GB0400804D0 (en) * | 2004-01-14 | 2004-02-18 | Innoscience Technology Bv | Pharmaceutical compositions |
| JP4746856B2 (ja) * | 2004-08-12 | 2011-08-10 | 三笠製薬株式会社 | ピラゾロン系製剤 |
| US20060110415A1 (en) * | 2004-11-22 | 2006-05-25 | Bioderm Research | Topical Delivery System for Cosmetic and Pharmaceutical Agents |
| JP5144277B2 (ja) * | 2005-01-14 | 2013-02-13 | カムルス エービー | 局所用生体付着性製剤 |
| US20070021411A1 (en) * | 2005-05-11 | 2007-01-25 | Cloyd James C | Supersaturated benzodiazepine solutions and their delivery |
| TW200824693A (en) * | 2006-08-28 | 2008-06-16 | Jazz Pharmaceuticals Inc | Pharmaceutical compositions of clonazepam and methods of use thereof |
| CA2669705A1 (en) * | 2006-11-21 | 2008-05-29 | Novartis Ag | Stable parenteral formulation containing a rsv inhibitor of a benzodiazepine structure |
-
2008
- 2008-01-18 CN CN200880005593.3A patent/CN101678112B/zh active Active
- 2008-01-18 CN CN201610674407.1A patent/CN106420614A/zh active Pending
- 2008-01-18 WO PCT/US2008/051466 patent/WO2008089426A2/en not_active Ceased
- 2008-01-18 AU AU2008206105A patent/AU2008206105B2/en active Active
- 2008-01-18 CN CN201610672083.8A patent/CN106389330A/zh active Pending
- 2008-01-18 EP EP16195222.1A patent/EP3150230A1/en not_active Withdrawn
- 2008-01-18 PL PL08705994T patent/PL2121025T3/pl unknown
- 2008-01-18 JP JP2009546547A patent/JP5877939B2/ja active Active
- 2008-01-18 EP EP08705994.5A patent/EP2121025B1/en active Active
- 2008-01-18 DK DK08705994.5T patent/DK2121025T3/en active
- 2008-01-18 HU HUE08705994A patent/HUE031463T2/en unknown
- 2008-01-18 CA CA2676010A patent/CA2676010C/en active Active
- 2008-01-18 ES ES08705994.5T patent/ES2611995T3/es active Active
-
2009
- 2009-07-16 IL IL199904A patent/IL199904A/en not_active IP Right Cessation
-
2013
- 2013-08-19 JP JP2013169582A patent/JP2013231089A/ja active Pending
-
2015
- 2015-11-27 JP JP2015231350A patent/JP6084277B2/ja active Active
-
2016
- 2016-12-08 JP JP2016238150A patent/JP6295314B2/ja active Active
-
2017
- 2017-06-15 JP JP2017117506A patent/JP2017155060A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017048250A5 (https=) | ||
| JP5250848B2 (ja) | Ａ２ｂアデノシン受容体拮抗物質を用いる肝疾患の予防および処置の方法 | |
| US10052333B2 (en) | Methods and systems for the delivery of a therapeutic agent | |
| US20090233912A1 (en) | Non-aqueous pharmaceutical composition | |
| ES2611995T3 (es) | Métodos y composiciones para el suministro de un agente terapéutico | |
| EP3110509B1 (en) | Treating cancer with a combination comprising dinaciclib | |
| JP2017203033A5 (https=) | ||
| FI3735295T3 (fi) | Parannetut peptidilääkkeet nashin ja muiden sairauksien hoitoon | |
| KR20230041081A (ko) | 비내용 테스토스테론 바이오-접착제 겔 제형 및 남성의 성선기능저하증을 치료하기 위한 그의 용도 | |
| PT1933809E (pt) | Composições para administração por via nasal | |
| AU2021247378A1 (en) | Formulation | |
| JP2001524108A (ja) | 局所経鼻抗炎症組成物 | |
| JP2021038250A (ja) | 眼の病状の治療方法 | |
| TWI853940B (zh) | 以組蛋白去乙醯酶抑制劑治療病毒相關癌症之方法 | |
| ES2285238T3 (es) | Combinacion de etabonato de loteprednol y dfho para el tratamiento de enfermedades de las vias respiratorias, enfermedades alergicas, asma y copd. | |
| KR101802011B1 (ko) | 원반성 루푸스에 사용하기 위한 2,4 치환 피리미딘디아민 | |
| JP2002539240A (ja) | エアロゾル噴射剤に溶解した薬剤 | |
| ES2291618T3 (es) | Composicion farmaceutica a base de un agente inhibidor de la pde4 o de la pde3/4 y de un agente antagonista de receptores de histamina. | |
| JP4929173B2 (ja) | Ａ２ｂアデノシンレセプターアンタゴニストを使用する創傷治癒の方法 | |
| KR20190041509A (ko) | Olig2 활성의 억제 | |
| CN109172546A (zh) | 利多卡因凝胶贴膏 | |
| Saadat et al. | The formulation, chemical and physical characterisation of clarithromycin-based macrolide solution pressurised metered dose inhaler | |
| CN100421649C (zh) | 含地西泮的经鼻微乳 | |
| EP2030610A1 (en) | Non-aqueous pharmaceutical compositions | |
| Davis | Further developments in nasal drug delivery |